Kazia Therapeutics (KZIA) Share-based Compensation (2016 - 2023)

Kazia Therapeutics' (KZIA) quarterly Share-based Compensation came in at $466900.5 in Q4 2021, up 109.23% YoY from $223154.4 in Q4 2020, and up 109.23% on a QoQ basis from $223154.4 in Q4 2020.

Kazia Therapeutics (KZIA) Share-based Compensation (2016 - 2023) Analysis & Trends

Kazia Therapeutics (KZIA) has 3 years of Share-based Compensation data on file, last reported at $466900.5 in Q4 2021.

  • Quarterly Share-based Compensation rose 109.23% year-over-year to $466900.5 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $1.5 million (up 20.27% YoY) and the FY2025 annual result came in at $418202.9, up 19.06% from the prior year.
  • Share-based Compensation advanced to $466900.5 in Q4 2021, from $223154.4 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $466900.5 in Q4 2021 to a low of $223154.4 in Q4 2020.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 108.10 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 243.00 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 277.20 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 137.41 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 590,899.88
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 86.63 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 41.25 Mn
10 Kazia Therapeutics 4.22 Bn 4.22 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 284,134.56
Dec 31, 2023 284,134.56
Dec 31, 2022 620,705.58
Dec 31, 2022 620,705.58
Dec 31, 2021 466,900.49
Dec 31, 2021 466,900.49
Dec 31, 2020 223,154.39
Dec 31, 2020 223,154.39
Dec 31, 2016 302,367.09
Dec 31, 2016 302,367.09